AU2007336538B2 - Substituted acetophenones useful as PDE4 inhibitors - Google Patents

Substituted acetophenones useful as PDE4 inhibitors Download PDF

Info

Publication number
AU2007336538B2
AU2007336538B2 AU2007336538A AU2007336538A AU2007336538B2 AU 2007336538 B2 AU2007336538 B2 AU 2007336538B2 AU 2007336538 A AU2007336538 A AU 2007336538A AU 2007336538 A AU2007336538 A AU 2007336538A AU 2007336538 B2 AU2007336538 B2 AU 2007336538B2
Authority
AU
Australia
Prior art keywords
compound
pyridin
dichloro
dimethoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007336538A
Other languages
English (en)
Other versions
AU2007336538A1 (en
Inventor
Jakob Felding
Simon Feldbaek Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of AU2007336538A1 publication Critical patent/AU2007336538A1/en
Application granted granted Critical
Publication of AU2007336538B2 publication Critical patent/AU2007336538B2/en
Priority to AU2012203892A priority Critical patent/AU2012203892A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007336538A 2006-12-22 2007-12-21 Substituted acetophenones useful as PDE4 inhibitors Ceased AU2007336538B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012203892A AU2012203892A1 (en) 2006-12-22 2012-07-03 Substituted acetophenones useful as PDE4 inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87168906P 2006-12-22 2006-12-22
US60/871,689 2006-12-22
US94547007P 2007-06-21 2007-06-21
US60/945,470 2007-06-21
PCT/DK2007/000564 WO2008077404A1 (en) 2006-12-22 2007-12-21 Substituted acetophenones useful as pde4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012203892A Division AU2012203892A1 (en) 2006-12-22 2012-07-03 Substituted acetophenones useful as PDE4 inhibitors

Publications (2)

Publication Number Publication Date
AU2007336538A1 AU2007336538A1 (en) 2008-07-03
AU2007336538B2 true AU2007336538B2 (en) 2012-04-05

Family

ID=39156588

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007336538A Ceased AU2007336538B2 (en) 2006-12-22 2007-12-21 Substituted acetophenones useful as PDE4 inhibitors

Country Status (23)

Country Link
US (3) US8148537B2 (cg-RX-API-DMAC10.html)
EP (1) EP2125736B1 (cg-RX-API-DMAC10.html)
JP (1) JP5342451B2 (cg-RX-API-DMAC10.html)
KR (1) KR101507717B1 (cg-RX-API-DMAC10.html)
AT (1) ATE503742T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007336538B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0721113A2 (cg-RX-API-DMAC10.html)
CA (1) CA2673370C (cg-RX-API-DMAC10.html)
CR (1) CR10877A (cg-RX-API-DMAC10.html)
CY (1) CY1111596T1 (cg-RX-API-DMAC10.html)
DE (1) DE602007013617D1 (cg-RX-API-DMAC10.html)
DK (1) DK2125736T3 (cg-RX-API-DMAC10.html)
GT (1) GT200900172A (cg-RX-API-DMAC10.html)
HR (1) HRP20110464T1 (cg-RX-API-DMAC10.html)
IL (1) IL199383A (cg-RX-API-DMAC10.html)
MX (1) MX2009006593A (cg-RX-API-DMAC10.html)
MY (1) MY146022A (cg-RX-API-DMAC10.html)
NO (1) NO20092372L (cg-RX-API-DMAC10.html)
NZ (1) NZ577863A (cg-RX-API-DMAC10.html)
PL (1) PL2125736T3 (cg-RX-API-DMAC10.html)
PT (1) PT2125736E (cg-RX-API-DMAC10.html)
RU (1) RU2493149C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008077404A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012007234A (es) 2009-12-22 2012-07-30 Leo Pharma As Nanocristales de monohidrato de calciprotiol.
RU2560677C2 (ru) 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
MX2012007225A (es) 2009-12-22 2012-07-30 Leo Pharma As Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
WO2014083099A1 (en) * 2012-11-30 2014-06-05 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
WO2014096018A1 (en) * 2012-12-19 2014-06-26 Leo Pharma A/S Methods for the preparation of substituted acetophenones
AU2014339136C1 (en) * 2013-10-22 2019-10-31 Chiesi Farmaceutici S.P.A. Process for the preparation of a PDE4 inhibitor
JP6785666B2 (ja) 2014-06-23 2020-11-18 レオ ファーマ アクティーゼルスカブ １，３−ベンゾジオキソール複素環化合物の調製方法
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
DK3390407T3 (da) 2015-12-18 2023-11-06 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
KR101702648B1 (ko) * 2016-05-10 2017-02-03 주식회사 엑티브온 피부 외용제용 보존제, 이를 포함하는 화장료 조성물 및 약학 조성물
AU2018286964B2 (en) 2017-06-20 2022-04-14 UNION therapeutics A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EP3838967A1 (en) 2019-12-16 2021-06-23 Spago Nanomedical AB Immobilization of phenolic compounds
CN117924243B (zh) * 2024-01-16 2025-09-12 沈阳药科大学 一种喹啉衍生物及其药用组合物和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0943613A1 (en) * 1996-11-19 1999-09-22 Kyowa Hakko Kogyo Kabushiki Kaisha Oxygenic heterocyclic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (cg-RX-API-DMAC10.html) * 1992-12-23 1995-11-21 Celltech Ltd
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
HK1000785A1 (en) * 1995-05-19 2006-06-30 Kyowa Hakko Kogyo Co., Ltd Oxygen-containing heterocyclic compounds
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
EP1621196A4 (en) * 2003-03-17 2007-03-21 Kyowa Hakko Kogyo Kk THERAPEUTIC AND / OR PREVENTIVE AGENT FOR CHRONIC SKIN DISEASES
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
US20070049611A1 (en) * 2005-06-10 2007-03-01 Talamas Francisco X Phosphodiesterase 4 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0943613A1 (en) * 1996-11-19 1999-09-22 Kyowa Hakko Kogyo Kabushiki Kaisha Oxygenic heterocyclic compounds

Also Published As

Publication number Publication date
US8497380B2 (en) 2013-07-30
DE602007013617D1 (de) 2011-05-12
JP5342451B2 (ja) 2013-11-13
CY1111596T1 (el) 2015-10-07
KR101507717B1 (ko) 2015-04-08
US20130012716A1 (en) 2013-01-10
HK1135392A1 (en) 2010-06-04
MX2009006593A (es) 2009-07-02
CA2673370A1 (en) 2008-07-03
JP2010513334A (ja) 2010-04-30
HRP20110464T1 (hr) 2011-07-31
ATE503742T1 (de) 2011-04-15
BRPI0721113A2 (pt) 2014-10-07
KR20090098990A (ko) 2009-09-18
US20100035908A1 (en) 2010-02-11
NZ577863A (en) 2012-04-27
GT200900172A (es) 2011-10-05
NO20092372L (no) 2009-07-14
US8148537B2 (en) 2012-04-03
US20120165539A1 (en) 2012-06-28
PT2125736E (pt) 2011-07-01
RU2009128191A (ru) 2011-01-27
CA2673370C (en) 2015-11-17
DK2125736T3 (da) 2011-07-11
PL2125736T3 (pl) 2011-09-30
AU2007336538A1 (en) 2008-07-03
IL199383A (en) 2015-02-26
RU2493149C2 (ru) 2013-09-20
MY146022A (en) 2012-06-15
US8324394B2 (en) 2012-12-04
WO2008077404A1 (en) 2008-07-03
EP2125736B1 (en) 2011-03-30
EP2125736A1 (en) 2009-12-02
CR10877A (es) 2009-07-10

Similar Documents

Publication Publication Date Title
US8148537B2 (en) Substituted acetophenones useful as PDE4 inhibitors
NL1028947C2 (nl) Gesubstitueerde methylaryl- of heteroarylamideverbindingen.
KR102662215B1 (ko) 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
JP5254228B2 (ja) バニロイド受容体アンタゴニストとしての、新規化合物、その異性体またはその薬学的に許容される塩；並びにそれを含む医薬組成物
US9284295B2 (en) Tetrahydrobenzothiophene compound
KR102588982B1 (ko) 파네소이드 x 수용체 효능제 및 이의 용도
CN113939288A (zh) Mas相关g蛋白受体x4的调节剂及相关产物和方法
US20090062294A1 (en) Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
TWI583687B (zh) ２－氧雜－５－氮雜雙環［２．２．１］庚－３－基衍生物
KR20110025915A (ko) 오렉시닌 수용체 길항제로서 헤테로방향족 모노아마이드
CN101522674B (zh) 作为香草酸受体拮抗剂的新化合物或其药物学可接受的盐、及包含这些化合物的药物组合物
US8183239B2 (en) Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
CN101611005B (zh) 用作pde4抑制剂的取代的苯乙酮类
CN114787135A (zh) 经取代的咪唑甲酰胺及其在治疗医学病症中的用途
CN102137851B (zh) 作为香草素受体拮抗剂的化合物、其异构体或其药学可接受的盐以及包含它们的药物组合物
AU2012203892A1 (en) Substituted acetophenones useful as PDE4 inhibitors
TWI429433B (zh) 可供治療使用之經取代苯乙酮化物
HK1135392B (en) Substituted acetophenones useful as pde4 inhibitors
RS51736B (sr) Supstituisani acetofenoni korisni kao inhibitori pde4
CN120865048A (zh) Mas相关g蛋白受体x4调节剂及用途
TW200531959A (en) Formamide derivatives for the treatment of diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired